SG11202100989UA - Novel fusion protein specific for cd137 and pd-l1 - Google Patents
Novel fusion protein specific for cd137 and pd-l1Info
- Publication number
- SG11202100989UA SG11202100989UA SG11202100989UA SG11202100989UA SG11202100989UA SG 11202100989U A SG11202100989U A SG 11202100989UA SG 11202100989U A SG11202100989U A SG 11202100989UA SG 11202100989U A SG11202100989U A SG 11202100989UA SG 11202100989U A SG11202100989U A SG 11202100989UA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion protein
- protein specific
- novel fusion
- novel
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18186445 | 2018-07-31 | ||
| EP18204548 | 2018-11-06 | ||
| PCT/EP2019/070596 WO2020025659A1 (en) | 2018-07-31 | 2019-07-31 | Novel fusion protein specific for cd137 and pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100989UA true SG11202100989UA (en) | 2021-02-25 |
Family
ID=67480227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100989UA SG11202100989UA (en) | 2018-07-31 | 2019-07-31 | Novel fusion protein specific for cd137 and pd-l1 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20210363257A1 (en) |
| EP (2) | EP4249064A3 (en) |
| JP (1) | JP7482488B2 (en) |
| KR (1) | KR20210040103A (en) |
| CN (1) | CN112789292A (en) |
| AU (1) | AU2019315703A1 (en) |
| BR (1) | BR112020025263A2 (en) |
| CA (1) | CA3100119A1 (en) |
| CL (1) | CL2021000207A1 (en) |
| CY (1) | CY1126148T1 (en) |
| DK (1) | DK3830120T5 (en) |
| ES (1) | ES2948717T3 (en) |
| FI (1) | FI3830120T3 (en) |
| HR (1) | HRP20230590T2 (en) |
| HU (1) | HUE062320T2 (en) |
| IL (1) | IL279541A (en) |
| LT (1) | LT3830120T (en) |
| MD (1) | MD3830120T3 (en) |
| MX (1) | MX2021000401A (en) |
| PH (1) | PH12021550001A1 (en) |
| PL (1) | PL3830120T3 (en) |
| RS (1) | RS64343B9 (en) |
| SG (1) | SG11202100989UA (en) |
| SI (1) | SI3830120T1 (en) |
| TW (1) | TWI837156B (en) |
| WO (1) | WO2020025659A1 (en) |
| ZA (1) | ZA202100125B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022513693A (en) * | 2018-11-29 | 2022-02-09 | ハーバー・バイオメド・セラピューティクス・リミテッド | Anti-PD-L1 antibody preparation |
| KR20210146999A (en) * | 2019-03-29 | 2021-12-06 | 피어이스 파마슈티컬즈 게엠베하 | Inhalational administration of lipocalin muteins |
| EP4041772A4 (en) | 2019-10-11 | 2024-04-24 | Nanjing Leads Biolabs Co., Ltd. | Antibodies binding 4-1bb and uses thereof |
| US20230227568A1 (en) | 2020-06-05 | 2023-07-20 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1bb |
| CA3203718A1 (en) * | 2021-01-08 | 2022-07-14 | Jiawang Liu | Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof |
| CN115521379B (en) * | 2021-07-16 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | PD-1 antibodies and uses thereof |
| CN114736303A (en) * | 2022-03-17 | 2022-07-12 | 英诺湖医药(杭州)有限公司 | Bifunctional antibody for resisting PD-L1 and 4-1BB and medical application thereof |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| TW202428603A (en) * | 2022-09-21 | 2024-07-16 | 美商思進公司 | Novel fusion protein specific for cd137 and cd228 |
| CN116211860B (en) * | 2023-05-10 | 2023-08-22 | 细胞生态海河实验室 | Application of CK2 inhibitor CX4945 in preparation of medicines for preventing immune cell depletion in tumor treatment, inhibitor and combination |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH01215289A (en) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | Production of normal human serum albumin a through gene recombination |
| FR2649991B2 (en) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| ES2241710T3 (en) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | PROCEDURE TO PRODUCE MULTIVALENT PROTEINS FROM UNION TO ANTIGEN. |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (en) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | lipocalin muteins |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| ATE307597T1 (en) | 1998-06-08 | 2005-11-15 | Hoffmann La Roche | USE OF PEG-IFN-ALPHA AND RIBAVIRIN TO TREAT CHRONIC HEPATITIS C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| JP2009509535A (en) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | Proteinaceous drugs and their use |
| AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| AU2016258952C1 (en) * | 2015-05-04 | 2020-12-24 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| JP6783797B2 (en) * | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Anti-cancer fusion polypeptide |
| LT3298030T (en) * | 2015-05-18 | 2023-02-27 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| MX2018008308A (en) * | 2016-01-11 | 2019-05-15 | Inhibrx Inc | Multivalent and multispecific 41bb-binding fusion proteins. |
| CN108752476B (en) * | 2016-03-04 | 2019-09-20 | 四川科伦博泰生物医药股份有限公司 | A kind of PDL-1 antibody, its medical composition and its use |
| WO2017215590A1 (en) * | 2016-06-13 | 2017-12-21 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
| WO2018087108A1 (en) * | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| CN107082812B (en) * | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | It is a kind of restore debilitating immune cell function fusion protein and its application |
| JP7145895B2 (en) * | 2017-09-01 | 2022-10-03 | 四川科倫博泰生物医薬股▲フン▼有限公司 | recombinant bispecific antibody |
| WO2023000675A1 (en) * | 2021-07-23 | 2023-01-26 | 安徽安科生物工程（集团）股份有限公司 | Bispecific antibody targeting pd-l1 and 4-1bb |
-
2019
- 2019-07-31 FI FIEP19746089.2T patent/FI3830120T3/en active
- 2019-07-31 CN CN201980050587.8A patent/CN112789292A/en active Pending
- 2019-07-31 HU HUE19746089A patent/HUE062320T2/en unknown
- 2019-07-31 CA CA3100119A patent/CA3100119A1/en active Pending
- 2019-07-31 BR BR112020025263-8A patent/BR112020025263A2/en unknown
- 2019-07-31 RS RS20230461A patent/RS64343B9/en unknown
- 2019-07-31 EP EP23167877.2A patent/EP4249064A3/en active Pending
- 2019-07-31 ES ES19746089T patent/ES2948717T3/en active Active
- 2019-07-31 MD MDE20210513T patent/MD3830120T3/en unknown
- 2019-07-31 SG SG11202100989UA patent/SG11202100989UA/en unknown
- 2019-07-31 TW TW108127283A patent/TWI837156B/en active
- 2019-07-31 MX MX2021000401A patent/MX2021000401A/en unknown
- 2019-07-31 KR KR1020217006003A patent/KR20210040103A/en unknown
- 2019-07-31 WO PCT/EP2019/070596 patent/WO2020025659A1/en active Application Filing
- 2019-07-31 LT LTEPPCT/EP2019/070596T patent/LT3830120T/en unknown
- 2019-07-31 PL PL19746089.2T patent/PL3830120T3/en unknown
- 2019-07-31 EP EP19746089.2A patent/EP3830120B9/en active Active
- 2019-07-31 AU AU2019315703A patent/AU2019315703A1/en active Pending
- 2019-07-31 SI SI201930558T patent/SI3830120T1/en unknown
- 2019-07-31 DK DK19746089.2T patent/DK3830120T5/en active
- 2019-07-31 US US17/264,080 patent/US20210363257A1/en active Pending
- 2019-07-31 HR HRP20230590TT patent/HRP20230590T2/en unknown
- 2019-07-31 JP JP2021529519A patent/JP7482488B2/en active Active
-
2020
- 2020-12-17 IL IL279541A patent/IL279541A/en unknown
-
2021
- 2021-01-01 PH PH12021550001A patent/PH12021550001A1/en unknown
- 2021-01-07 ZA ZA2021/00125A patent/ZA202100125B/en unknown
- 2021-01-26 CL CL2021000207A patent/CL2021000207A1/en unknown
-
2023
- 2023-06-29 CY CY20231100305T patent/CY1126148T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202100125B (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| GB2564823B (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
| EP3880814A4 (en) | Fusion protein | |
| EP3298033A4 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
| EP3348571A4 (en) | Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof | |
| EP3287470A4 (en) | Novel recombinant bi-functional fusion protein and preparation and application therefor | |
| IL284687A (en) | Novel fusion proteins specific for cd137 and gpc3 | |
| EP3280727A4 (en) | Single-arm type i and type ii receptor fusion proteins and uses thereof | |
| SG11202008721SA (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| EP3147298A4 (en) | Pd-l1 fusion protein and use thereof | |
| IL287318A (en) | Materials and methods for protein production | |
| SG11202101811VA (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| ZA202003845B (en) | Fusion proteins | |
| SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
| ZA202102533B (en) | Fusion protein | |
| IL291284A (en) | Systems and methods for protein expression | |
| IL281397B (en) | Human pd-l1 antibodies | |
| IL291236A (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| SG11202000775SA (en) | Fusion tags for recombinant protein expression | |
| EP3317297A4 (en) | Btla fusion protein agonists and uses thereof | |
| IL290715A (en) | Nkg2d fusion proteins and uses thereof | |
| EP4034565A4 (en) | Pd-l1 targeted chimeric proteins and uses thereof | |
| EP3740501A4 (en) | Fusion protein extensions | |
| EP3647426A4 (en) | Fusion protein |